Novartis announced 46 abstracts at MSToronto2026, including late-breaking Phase III REMODEL-1/-2 data for remibrutinib in relapsing MS and Phase III NEOS data for Kesimpta in pediatric MS. An investor call will follow the remibrutinib presentation.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
